1. For the 4-month period from September to December 2021, how many patients has your trust treated (using intra-vitreal injections or implants) for each of the following eye conditions:
1. Wet Age-Related Macular Degeneration (wAMD)
2. Diabetic Macular Oedema (DMO)
3. Retinal Vein Occlusion – Central (CRVO) or Branch (BRVO)
4. Any other eye condition
2. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2021:
1. Aflibercept
2. Bevacizumab
3. Brolucizumab
4. Dexamethasone
5. Fluocinolone acetonide
6. Ranibizumab
3. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2021.
Number of Injections/Implants: Sep to Dec 2021
Eye Conditions – wAMD, DMO, RVO
Treatment –
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Fluocinolone acetonide
Ranibizumab
